Japan’s ruling coalition sustained a crushing blow in the Lower House election last month, only managing to win 215 seats,…
HOME > BUSINESS
BUSINESS
- Takeda Sees Sales Rise on Expanding Europe, Emerging Market Biz in FY2012, Yet Operating Profit Sags 50%
May 10, 2013
- No Prospects of Reaching Agreement on Delivery Prices with Wholesalers Even after the Fiscal Year End: Pres. Tajiri of Medical System Network
May 10, 2013
- Eisai to Launch the Obesity Treatment Belviq in the US in June
May 10, 2013
- Ono, DSP to Expand Business for Limaprost in China
May 10, 2013
- Santen’s FY2012 Operating Profit Sinks 7% as Eylea Launch Drives Up Cost Ratio
May 9, 2013
- Astellas Partners with Drais Pharmaceuticals to Develop Nocturia Treatment
May 9, 2013
- MTPC Annual Sales Up 3% with Gilenya Royalities, Remicade Growth
May 9, 2013
- Baxter’s Cell Culture-Based Prototype Flu Vaccine Obtains Approval
May 9, 2013
- Takeda to Acquire US Dengue Vaccine Developer Inviragen
May 9, 2013
- Kowa to Initiate Domestic PI Clinical Study of Anticancer Drug Codeveloped by NanoCarrier
May 9, 2013
- IFRS Implications to Be Seen in In-Licensed Products, M&A Processing
May 9, 2013
- Maruishi Licenses New Kappa Opioid Agonist from Cara Therapeutics
May 8, 2013
- BMKK to Increase Number of MRs to 1,000 by 2015
May 8, 2013
- Astellas: FDA Advisory Panel Did Not Back Approval of Tivozanib
May 8, 2013
- Shionogi Sponsors EMPATHY Study to Build New Evidence for Statins
May 8, 2013
- AnGes MG Eyes PIII Trial for Collategene in US, Europe by 2013-End
May 8, 2013
- Nichi-Iko Voluntarily Recalls Enalapril Maleate Tablets
May 7, 2013
- BI Japan’s Ethical Drug Sales Up 7.3% with Prazaxa Sales of 23.5 Billion Yen
May 7, 2013
- Fujifilm Kyowa Kirin Biologics Looking for Marketing Partners in Europe and US: Executive VP Kawaguchi
May 7, 2013
- Mochida Files NDA for PAH Treatment Treprostinil
May 7, 2013
ページ
For over two decades, Morunda has been at the forefront of interviewing and understanding leaders within Japan’s dynamic healthcare industry, particularly in pharmaceuticals and medical devices. What sets apart successful country managers in this competitive arena isn’t just their professional…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…